G

Galapagos NV

D
GLPG
USD
0.465
(1.7222%)
Market Closed
9,050.00
Volume
-2.23
EPS
-
Div Yield
52.977
P/E
1,809,863,055.02
Market Cap
Today
2.5962%
1 Week
4.113%
1 Month
-9.147%
6 Months
-5.570%
12 Months
-27.800%
Year To Date
-32.435%
All Time
0%

Title:
Galapagos NV

Sector:
Healthcare
Industry:
Biotechnology
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
Do you need help or have a question?